STOCK TITAN

Ligand Pharmaceuticals, Inc. - LGND STOCK NEWS

Welcome to our dedicated news page for Ligand Pharmaceuticals (Ticker: LGND), a resource for investors and traders seeking the latest updates and insights on Ligand Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ligand Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ligand Pharmaceuticals's position in the market.

Rhea-AI Summary
Ligand Pharmaceuticals and Merck announce positive results from Phase 3 trials of V116 pneumococcal conjugate vaccine, potentially the first vaccine for adults. Results show statistically significant immune responses and a safety profile comparable to the comparator. Ligand is entitled to a royalty on worldwide net sales if approved.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
conferences earnings
-
Rhea-AI Summary
Ligand Pharmaceuticals has offered to acquire the assets of Novan for $15 million in cash and provide up to $15 million in debtor-in-possession financing. The transaction aims to preserve the value of Novan's business and berdazimer gel development assets. Ligand plans to out license or sell Novan's existing programs and commercial assets if the bid is successful. The proposed transaction is subject to court approval and is expected to close in Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.12%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
conferences earnings
Ligand Pharmaceuticals, Inc.

Nasdaq:LGND

LGND Rankings

LGND Stock Data

1.44B
16.67M
5.93%
94.12%
3.8%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About LGND

ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. we operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders.